Efficacy and safety of erythrocytapheresis in chronic mountain sickness: a randomised controlled trial protocol (ESCAPE-CMS).
Xin-Yi Shou, Qing Xiang, Jun Liang...
https://pubmed.ncbi.nlm.nih.gov/42833714/Actively Recruiting
Led by Third Military Medical University · Updated on 2026-08-25
112
Participants Needed
1
Research Sites
39 weeks
Total Duration
Researchers are evaluating the effectiveness and safety of erythrocytapheresis in people with Chronic Mountain Sickness CMS. This condition affects residents living at high altitudes, and the study aims to compare outcomes between those receiving erythrocytapheresis plus standard care and those receiving standard care alone. The trial focuses on how well this blood cell removal procedure works as a method to reduce hematocrit levels and improve symptoms. Participants will be randomly assigned to one of two groups. The intervention group will receive erythrocytapheresis, which involves removing a set amount of red blood cells using a machine, while their plasma and other blood components are returned to maintain blood volume. Both groups will continue with standard care, including oxygen therapy and basic medical management. Clinical assessments will be conducted shortly after treatment and during follow-up to compare symptoms and physical function. Throughout the study, participants will undergo evaluations such as symptom scoring for CMS, the Incremental Shuttle Walk Test to measure exercise capacity, blood oxygen levels, and monitoring for any complications from the procedure. These assessments will occur 48 to 72 hours after erythrocytapheresis or prior to discharge for the standard care group, and then periodically during follow-up. The research team will use this data to understand the potential benefits and safety of erythrocytapheresis over time.
CONDITIONS
Erythrocytapheresis for Chronic Mountain Sickness
J
Jieru Guo
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Third Military Medical University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 48 hours post-procedure or prior to discharge
Participants receive either erythrocytapheresis plus standard care or standard care alone, including oxygen therapy and medical management.
1 to 2 visits for assessments
Duration - During follow-up period
Participants undergo periodic assessments of symptoms, exercise capacity, blood oxygen levels, and safety monitoring after treatment.
Multiple follow-up visits
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Xin-Yi Shou, Qing Xiang, Jun Liang...
https://pubmed.ncbi.nlm.nih.gov/42833714/Third Military Medical University
Lead Sponsor